Sabal Trust CO raised its position in Eli Lilly and Company (NYSE:LLY) by 0.2% during the second quarter, Holdings Channel reports. The fund owned 6,410 shares of the company’s stock after buying an additional 10 shares during the period. Sabal Trust CO’s holdings in Eli Lilly and were worth $527,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the company. Juncture Wealth Strategies LLC boosted its position in Eli Lilly and by 54.8% in the second quarter. Juncture Wealth Strategies LLC now owns 4,800 shares of the company’s stock worth $395,000 after buying an additional 1,700 shares during the last quarter. Patriot Wealth Management Inc. boosted its position in shares of Eli Lilly and by 3.1% in the second quarter. Patriot Wealth Management Inc. now owns 71,726 shares of the company’s stock worth $5,903,000 after buying an additional 2,130 shares in the last quarter. Bollard Group LLC boosted its position in shares of Eli Lilly and by 0.5% in the second quarter. Bollard Group LLC now owns 315,482 shares of the company’s stock worth $25,964,000 after buying an additional 1,508 shares in the last quarter. Roanoke Asset Management Corp NY boosted its position in shares of Eli Lilly and by 38.9% in the second quarter. Roanoke Asset Management Corp NY now owns 38,840 shares of the company’s stock worth $3,197,000 after buying an additional 10,870 shares in the last quarter. Finally, Reilly Financial Advisors LLC boosted its position in shares of Eli Lilly and by 8.8% in the second quarter. Reilly Financial Advisors LLC now owns 18,857 shares of the company’s stock worth $1,552,000 after buying an additional 1,530 shares in the last quarter. Hedge funds and other institutional investors own 75.61% of the company’s stock.

Shares of Eli Lilly and Company (LLY) traded down 0.80% during midday trading on Thursday, reaching $81.91. The company had a trading volume of 947,323 shares. The stock has a market capitalization of $86.42 billion, a PE ratio of 35.44 and a beta of 0.34. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $86.72. The company’s 50-day moving average is $83.02 and its 200-day moving average is $81.68.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. The company had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.86 earnings per share. On average, equities research analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s payout ratio is 90.04%.

WARNING: “Eli Lilly and Company (LLY) Shares Bought by Sabal Trust CO” was published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/08/10/eli-lilly-and-company-lly-shares-bought-by-sabal-trust-co.html.

A number of brokerages recently issued reports on LLY. Berenberg Bank reiterated a “buy” rating and issued a $98.00 target price on shares of Eli Lilly and in a report on Friday, August 4th. BMO Capital Markets reiterated a “sell” rating and issued a $73.00 target price on shares of Eli Lilly and in a report on Friday, August 4th. TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a report on Tuesday, July 25th. UBS AG cut Eli Lilly and to a “hold” rating and set a $85.00 target price on the stock. in a report on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. cut Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 target price on the stock. in a report on Wednesday, July 26th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Eli Lilly and has an average rating of “Hold” and a consensus target price of $88.27.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 215,000 shares of the company’s stock in a transaction dated Tuesday, June 20th. The stock was sold at an average price of $83.05, for a total value of $17,855,750.00. Following the completion of the sale, the insider now owns 124,475,804 shares in the company, valued at $10,337,715,522.20. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Melissa S. Barnes sold 1,900 shares of the company’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $80.78, for a total value of $153,482.00. Following the completion of the sale, the insider now owns 14,041 shares of the company’s stock, valued at approximately $1,134,231.98. The disclosure for this sale can be found here. In the last 90 days, insiders sold 669,733 shares of company stock valued at $55,845,287. Company insiders own 0.20% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.